drugset / Trial / NCT05225857
A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objectives of the study are to assess the safety and tolerability of AGA2118 after single subcutaneous or intravenous administration in healthy men and postmenopausal women and to assess the safety and tolerability of AGA2118 after multiple subcutaneous administrations in men and postmenopausal women.
Timeline
- Start
- 2022-06-28
- Primary completion
- 2024-01-13
- Completion
- 2024-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGA2118 | Unknown | 0.3 mg/kg | Subcutaneous |
| Subject | AGA2118 | Unknown | 1 mg/kg | Subcutaneous |
| Subject | AGA2118 | Unknown | 12 mg/kg | Subcutaneous |
| Subject | AGA2118 | Unknown | 15 mg/kg | Subcutaneous |